Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor.

Pablo Tebas, Julie K Jadlowsky, Yuqi Zhou, M Betina Pampena, George J Leslie, Nan Liu, Sriram Srivatsa, Colby R Maldini, Jingxin Wang, Chungdhak Jaming Tsang, Ola Mohamed, Josephine Romano, Beth Haggarty, Gabriela Plesa, Avery L Gaymon